© Reuters. Veru (VERU) Shares Up 35% Pre-market on Overwhelming COVID-19 Oral Drug Efficacy
Veru Inc. (NASDAQ:) shares are gaining over 30% in heavy pre-market buying and selling after the corporate introduced that its COVID-19 drug candidate lowered deaths by 55% in hospitalized COVID sufferers in Section 3 trial. Because of the “overwhelming” efficacy of the research, Impartial Information Security Monitoring Committee unanimously really helpful that the Section 3 research be halted, they usually additional remarked that no security issues have been recognized.
:max_bytes(150000):strip_icc()/health-broccoli-vs-brussel-sprouts-template-1_720-c310b4225b194326b0f2e80f1478c02b.jpg "Which Packs a Greater Antioxidant Punch?")
